DORZOLAMIDE-TIMOLOL PF 5 MG
TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG · DIN 02542056 · MICRO LABS LIMITED
Health Canada status: APPROVED
What is DORZOLAMIDE-TIMOLOL PF?
DORZOLAMIDE-TIMOLOL PF 5 MG contains TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02542056, held by MICRO LABS LIMITED, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as approved, status dated 25-Oct-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02542056 |
|---|---|
| Brand name | DORZOLAMIDE-TIMOLOL PF |
| Generic / active ingredient | TIMOLOL (TIMOLOL MALEATE) : 5 MG DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) : 20 MG |
| Manufacturer | MICRO LABS LIMITED |
| Strength | 5 MG |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC |
| Schedule | Prescription |
| ATC code | S01ED51 TIMOLOL, COMBINATIONS |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 25-Oct-2023 |
What can be used instead?
Other Canadian products sharing ATC code S01ED51 TIMOLOL, COMBINATIONS. 21 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-BRIMONIDINE-TIMOP | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02375311 |
| APO-DORZO-TIMOP | 5 MG | SOLUTION | APOTEX INC | MARKETED | DIN 02299615 |
| APO-TRAVOPROST-TIMOP PQ | 0.5 % | SOLUTION | APOTEX INC | MARKETED | DIN 02415305 |
| AZARGA | 0.5 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02331624 |
| COMBIGAN | 0.2 % | SOLUTION | ABBVIE CORPORATION | MARKETED | DIN 02248347 |
| COSOPT | 5 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02240113 |
| COSOPT PRESERVATIVE-FREE | 20 MG | SOLUTION | ELVIUM LIFE SCIENCES | MARKETED | DIN 02258692 |
| DORZOLAMIDE-TIMOLOL | 20 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02522020 |
| DUOTRAV PQ | 0.5 % | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02278251 |
| JAMP BRIMONIDINE/TIMOLOL | 0.2 % | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02531704 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.